Q1 with 24% CER growth and 9-10% EBIT beat. Growth to accelerate firmly in remainder of 2024. Reiterate BUY, but little sentiment help from Q1 report.

03 May 2024
Lower-quality 24% CER growth in Q1

Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Lower-quality 24% CER growth in Q1
Novo Nordisk A/S Class B (NOVO.B:CSE) | 0 0 0.0%
- Published:
03 May 2024 -
Author:
ABGSC Healthcare Research | Morten Larsen -
Pages:
13 -
Q1 with 24% CER growth and 9-10% EBIT beat. Growth to accelerate firmly in remainder of 2024. Reiterate BUY, but little sentiment help from Q1 report.